No Data
No Data
Apeloa Pharmaceutical (000739.SZ): It is expected that the demand for antibiotics will rebound slightly in the second half of the year.
On August 20th, Glory Medicaments reported at the investor relations event that the overall API sector of Apeloa Pharmaceutical (000739.SZ) is still under some pressure and there are no clear signs of rebound at the moment, especially for animal medicine and sartans. In terms of animal medicine, although pork prices are rising, animal medicine is still at a low level, such as flunixin. Sartans are also at their historical lows. Cephalosporin and penicillin are the company's two largest categories with a relatively stable competitive landscape, but demand has been weaker than in previous years since April, and it is expected that after pharmacy price comparisons, the end market inventory will be more cautious in the second half of the year.
Apeloa Pharmaceutical's H1 Profit Up 4%, Revenue Rises 8%; Shares Climb 3%
Apeloa Pharmaceutical: Summary of Half-Year Report in 2024.
Apeloa Pharmaceutical: Half-year report for the year 2024.
Apeloa Pharmaceutical (000739.SZ): net income of 625 million yuan in the first half of the year, a year-on-year increase of 3.96%.
Apeloa Pharmaceuticals (000739.SZ) announced its half-yearly report. During the reporting period, the company achieved a revenue of 6.429 billion yuan, a year-on-year increase of 7.96%, and a net profit attributable to shareholders of the listed company of 0.625 billion yuan, a year-on-year increase of 3.96%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.6 billion yuan, a year-on-year increase of 1.24%. In the first half of 2024, international geopolitical tensions are still complex, industry competition remains fierce, and the domestic economic recovery is still weak, and the investment and financing environment is still severe, which has brought great pressure and challenges to the company's operation and development.
Apeloa Pharmaceutical (000739.SZ) currently does not have any products related to vitamins.
Apeloa Pharmaceutical (000739.SZ) stated on the investor interaction platform on August 12th that, at present, the company does not have any vitamin-related products.
No Data